OTC · ONPH
Oncology Pharma Inc.
$0.04+$0.01 (+19.6%)
Oncology Pharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.11% below the high.
Loading market information…
OTC · PANC · USD
Stock price
Quote as of Oct 28, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Panacos Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE COMPANY BEHIND THE TICKER
Panacos Pharmaceuticals, Inc. functions as an early-stage biotechnology firm specializing in the research and development of orally administered small-molecule therapeutics. These innovative drugs are crafted to combat human immunodeficiency virus (HIV) and various other viral diseases affecting humans. The company's scientific methodology concentrates on identifying novel targets within the viral life cycle, specifically focusing on processes like virus maturation and fusion. Currently, their product portfolio includes advanced initiatives, such as second- and third-generation programs, centered on inhibiting HIV maturation. Founded in 1999, the company's main operations are situated in Watertown, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:54 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.04+$0.01 (+19.6%)
Oncology Pharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.11% below the high.
$0.00$0.00 (0.0%)
Wuhan General Group (China), Inc.’s quoted price sits in the lower half of its reported 52-week range, 60.0% below the high.
$0.00$0.00 (0.0%)
Better Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
$0.00$0.00 (0.0%)
Inyx, Inc.: Healthcare · Medical - Pharmaceuticals.
$0.00$0.00 (0.0%)
Arno Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
$0.00$0.00 (0.0%)
Innovation1 Biotech Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
Baudax Bio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
Kaleido Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.95% below the high.
